Publications
-
Inflammatory arthritis following ustekinumab treatment for psoriasis: a report of two cases.
de Souza A,
Ali-Shaw T, Reddy SM, Fiorentino D, Strober BE.
Br J Dermatol.
2013;
168
(1):
210-2
-
Localized cutaneous fibrosing disorders.
Yaqub A,
Chung L, Rieger KE, Fiorentino DF.
Rheum Dis Clin North Am.
2013;
39
(2):
347-64
-
A novel dermato-pulmonary syndrome associated with MDA-5 antibodies: report of 2 cases and review of the literature.
Chaisson NF,
Paik J, Orbai AM, Casciola-Rosen L, Fiorentino D, Danoff S, Rosen A.
Medicine (Baltimore).
2012;
91
(4):
220-8
-
Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection.
Fiorentino D,
Casciola-Rosen L.
Arthritis Rheum.
2012;
64
(2):
346-9
-
Clinical presentation and evaluation of dermatomyositis.
Marvi U,
Chung L, Fiorentino DF.
Indian J Dermatol.
2012;
57
(5):
375-81
-
Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment.
Strand V,
Sharp V, Koenig AS, Park G, Shi Y, Wang B, Zack DJ, Fiorentino D.
Ann Rheum Dis.
2012;
71
(7):
1143-50
-
Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients.
Higgs BW,
Zhu W, Richman L, Fiorentino DF, Greenberg SA, Jallal B, Yao Y.
Int J Rheum Dis.
2012;
15
(1):
25-35
-
Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases.
Wong D,
Kea B, Pesich R, Higgs BW, Zhu W, Brown P, Yao Y, Fiorentino D.
PLoS One.
2012;
7
(1):
e29161
-
Skin disease in dermatomyositis.
Zaba LC,
Fiorentino DF.
Curr Opin Rheumatol.
2012;
24
(6):
597-601
-
A pilot study of etanercept treatment for pemphigus vulgaris.
Fiorentino DF,
Garcia MS, Rehmus W, Kimball AB.
Arch Dermatol.
2011;
147
(1):
117-8
-
Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis.
Arefiev K,
Fiorentino DF, Chung L.
Int J Rheumatol.
2011:
2011
201787
-
Pathogenesis of dermatomyositis: role of cytokines and interferon.
Kao L,
Chung L, Fiorentino DF.
Curr Rheumatol Rep.
2011;
13
(3):
225-32
-
The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes.
Fiorentino DF,
Chen RO, Stewart DB, Brown KK, Sundram UN.
Br J Dermatol.
2011;
164
(5):
996-1003
-
The mucocutaneous and systemic phenotype of dermatomyositis patients with antibodies to MDA5 (CADM-140): a retrospective study.
Fiorentino D,
Chung L, Zwerner J, Rosen A, Casciola-Rosen L.
J Am Acad Dermatol.
2011;
65
(1):
25-34
-
Tyrosine kinases in inflammatory dermatologic disease.
Paniagua RT,
Fiorentino DF, Chung L, Robinson WH.
J Am Acad Dermatol.
2011;
65
(2):
389-403
-
Conditioned pharmacotherapeutic effects: a preliminary study.
Ader R,
Mercurio MG, Walton J, James D, Davis M, Ojha V, Kimball AB, Fiorentino D.
Psychosom Med.
2010;
72
(2):
192-7
-
Imatinib in the treatment of nephrogenic systemic fibrosis.
Chandran S,
Petersen J, Jacobs C, Fiorentino D, Doeden K, Lafayette RA.
Am J Kidney Dis.
2009;
53
(1):
129-32
-
MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.
Chung L,
Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin RW, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Gilbert A, Dechow FJ, Gregory J, Wigley FM.
Arthritis Rheum.
2009;
60
(3):
870-7
-
Molecular framework for response to imatinib mesylate in systemic sclerosis.
Chung L,
Fiorentino DF, Benbarak MJ, Adler AS, Mariano MM, Paniagua RT, Milano A, Connolly MK, Ratiner BD, Wiskocil RL, Whitfield ML, Chang HY, Robinson WH.
Arthritis Rheum.
2009;
60
(2):
584-91
-
Palisaded neutrophilic and granulomatous dermatitis associated with limited systemic sclerosis.
Hantash BM,
Chiang D, Kohler S, Fiorentino D.
J Am Acad Dermatol.
2008;
58
(4):
661-4
-
Type I interferon in the induction or exacerbation of dermatomyositis: what this observation tells us about the naturally occurring disease.
Fiorentino DF,
Arch Dermatol.
2008;
144
(10):
1379-82
-
Mycophenolate mofetil.
Zwerner J,
Fiorentino D.
Dermatol Ther.
2007 Jul-Aug;
20
(4):
229-38
-
A pilot trial of rituximab in the treatment of patients with dermatomyositis.
Chung L,
Genovese MC, Fiorentino DF.
Arch Dermatol.
2007;
143
(6):
763-7
-
Localized scleroderma and systemic sclerosis: is there a connection?
Gupta RA,
Fiorentino D.
Best Pract Res Clin Rheumatol.
2007;
21
(6):
1025-36
-
Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis.
Richmond H,
Zwerner J, Kim Y, Fiorentino D.
Arch Dermatol.
2007;
143
(8):
1025-30
-
Systemic and localized scleroderma.
Chung L,
Lin J, Furst DE, Fiorentino D.
Clin Dermatol.
2006 Sep-Oct;
24
(5):
374-92
-
A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis.
Chung L,
Fiorentino D.
J Am Acad Dermatol.
2006;
54
(5):
880-2
-
Digital ulcers in patients with systemic sclerosis.
Chung L,
Fiorentino D.
Autoimmun Rev.
2006;
5
(2):
125-8
-
Liver enzyme abnormalities in patients with atopic dermatitis treated with mycophenolate mofetil.
Hantash B,
Fiorentino D.
Arch Dermatol.
2006;
142
(1):
109-10
-
Successful use of rituximab for cutaneous vasculitis.
Chung L,
Funke AA, Chakravarty EF, Callen JP, Fiorentino DF.
Arch Dermatol.
2006;
142
(11):
1407-10
-
Update on cutaneous vasculitis.
Grzeszkiewicz TM,
Fiorentino DF.
Semin Cutan Med Surg.
2006;
25
(4):
221-5
-
Muir-Torre syndrome: confirmation of diagnosis by immunohistochemical analysis of cutaneous lesions.
Fiorentino DF,
Nguyen JC, Egbert BM, Swetter SM.
J Am Acad Dermatol.
2004;
50
(3):
476-8
-
Cutaneous vasculitis.
Fiorentino DF,
J Am Acad Dermatol.
2003;
48
(3):
311-40
-
Characterization of Saccharomyces cerevisiae dna2 mutants suggests a role for the helicase late in S phase.
Fiorentino DF,
Crabtree GR.
Mol Biol Cell.
1997;
8
(12):
2519-37
-
The mechanism of action of cyclosporin A and FK506.
Ho S,
Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, Nourse J, Crabtree GR.
Clin Immunol Immunopathol.
1996;
80
(3 Pt 2):
S40-5
-
TOR kinase domains are required for two distinct functions, only one of which is inhibited by rapamycin.
Zheng XF,
Florentino D, Chen J, Crabtree GR, Schreiber SL.
Cell.
1995;
82
(1):
121-30
-
Immunophilins interact with calcineurin in the absence of exogenous immunosuppressive ligands.
Cardenas ME,
Hemenway C, Muir RS, Ye R, Fiorentino D, Heitman J.
EMBO J.
1994;
13
(24):
5944-57
-
Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes.
Clipstone NA,
Fiorentino DF, Crabtree GR.
J Biol Chem.
1994;
269
(42):
26431-7
-
Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase.
Kuo CJ,
Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR.
Nature.
1992;
358
(6381):
70-3
-
Diversity of cytokine synthesis and function of mouse CD4+ T cells.
Mosmann TR,
Schumacher JH, Street NF, Budd R, O'Garra A, Fong TA, Bond MW, Moore KW, Sher A, Fiorentino DF.
Immunol Rev.
1991:
123
209-29
-
IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.
Fiorentino DF,
Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A.
J Immunol.
1991;
146
(10):
3444-51
-
IL-10 inhibits cytokine production by activated macrophages.
Fiorentino DF,
Zlotnik A, Mosmann TR, Howard M, O'Garra A.
J Immunol.
1991;
147
(11):
3815-22
-
Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI.
Vieira P,
de Waal-Malefyt R, Dang MN, Johnson KE, Kastelein R, Fiorentino DF, deVries JE, Roncarolo MG, Mosmann TR, Moore KW.
Proc Natl Acad Sci U S A.
1991;
88
(4):
1172-6
-
Production of IL-10 by CD4+ T lymphocytes correlates with down-regulation of Th1 cytokine synthesis in helminth infection.
Sher A,
Fiorentino D, Caspar P, Pearce E, Mosmann T.
J Immunol.
1991;
147
(8):
2713-6
-
Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1.
Hsu DH,
de Waal Malefyt R, Fiorentino DF, Dang MN, Vieira P, de Vries J, Spits H, Mosmann TR, Moore KW.
Science.
1990;
250
(4982):
830-2
-
Heterogeneity of mouse helper T cells. Evidence from bulk cultures and limiting dilution cloning for precursors of Th1 and Th2 cells.
Street NE,
Schumacher JH, Fong TA, Bass H, Fiorentino DF, Leverah JA, Mosmann TR.
J Immunol.
1990;
144
(5):
1629-39
-
Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI.
Moore KW,
Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR.
Science.
1990;
248
(4960):
1230-4
-
Isolation of monoclonal antibodies specific for IL-4, IL-5, IL-6, and a new Th2-specific cytokine (IL-10), cytokine synthesis inhibitory factor, by using a solid phase radioimmunoadsorbent assay.
Mosmann TR,
Schumacher JH, Fiorentino DF, Leverah J, Moore KW, Bond MW.
J Immunol.
1990;
145
(9):
2938-45
-
Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.
Fiorentino DF,
Bond MW, Mosmann TR.
J Exp Med.
1989;
170
(6):
2081-95
Navigation for This Section: Dermatology
Additinal Links: regular features
Find a Researcher
Help
Derm Intranet